Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humora...
Saved in:
Published in | Molecules and cells Vol. 44; no. 6; pp. 392 - 400 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
United States
Korean Society for Molecular and Cellular Biology
01.06.2021
한국분자세포생물학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1016-8478 0219-1032 |
DOI | 10.14348/molcells.2021.0075 |
Cover
Summary: | It has been more than a year since severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first emerged. Many studies have provided insights into the various aspects of the immune response in coronavirus disease 2019 (COVID-19). Especially for antibody treatment and vaccine development, humoral immunity to SARS-CoV-2 has been studied extensively, though there is still much that is unknown and controversial. Here, we introduce key discoveries on the humoral immune responses in COVID-19, including the immune dynamics of antibody responses and correlations with disease severity, neutralizing antibodies and their cross-reactivity, how long the antibody and memory B-cell responses last, aberrant autoreactive antibodies generated in COVID-19 patients, and the efficacy of currently available therapeutic antibodies and vaccines against circulating SARS-CoV-2 variants, and highlight gaps in the current knowledge. |
---|---|
ISSN: | 1016-8478 0219-1032 |
DOI: | 10.14348/molcells.2021.0075 |